BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6143040)

  • 1. Human recombinant interleukin-2 partly reconstitutes deficient in-vitro immune responses of lymphocytes from patients with AIDS.
    Lifson JD; Benike CJ; Mark DF; Koths K; Engleman EG
    Lancet; 1984 Mar; 1(8379):698-702. PubMed ID: 6143040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of systemic in vivo interleukin-2 (IL-2) reconstitution in patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC) on phenotypes and functions of peripheral blood mononuclear cells (PBMC).
    Ernst M; Kern P; Flad HD; Ulmer AJ
    J Clin Immunol; 1986 Mar; 6(2):170-81. PubMed ID: 2940258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.
    Rook AH; Masur H; Lane HC; Frederick W; Kasahara T; Macher AM; Djeu JY; Manischewitz JF; Jackson L; Fauci AS; Quinnan GV
    J Clin Invest; 1983 Jul; 72(1):398-403. PubMed ID: 6308051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
    Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
    J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS patients.
    Zerhouni B; Sanhadji K; Kehrli L; Livrozet JM; Touraine JL
    Thymus; 1997; 24(3):147-56. PubMed ID: 9151380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
    Lanier LL; Benike CJ; Phillips JH; Engleman EG
    J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome.
    Murray HW; Welte K; Jacobs JL; Rubin BY; Mertelsmann R; Roberts RB
    J Clin Invest; 1985 Nov; 76(5):1959-64. PubMed ID: 2997299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
    Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
    Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoregulatory circuits in the acquired immune deficiency syndrome and related complex. Production of and response to interleukins 1 and 2, NK function and its enhancement by interleukin-2 and kinetics of the autologous mixed lymphocyte reaction.
    Alcocer-Varela J; Alarcon-Segovia D; Abud-Mendoza C
    Clin Exp Immunol; 1985 Apr; 60(1):31-8. PubMed ID: 3159524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
    Phillips JH; Gemlo BT; Myers WW; Rayner AA; Lanier LL
    J Clin Oncol; 1987 Dec; 5(12):1933-41. PubMed ID: 3500280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism.
    Rook AH; Hooks JJ; Quinnan GV; Lane HC; Manischewitz JF; Macher AM; Masur H; Fauci AS; Djeu JY
    J Immunol; 1985 Mar; 134(3):1503-7. PubMed ID: 3918102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic events taking place in the lung of patients with HIV-1 infection. Evidence of an intrinsic defect of the major histocompatibility complex-unrestricted killing partially restored by the incubation with rIL-2.
    Agostini C; Zambello R; Trentin L; Feruglio C; Masciarelli M; Siviero F; Poletti V; Spiga L; Gritti F; Semenzato G
    Am Rev Respir Dis; 1990 Sep; 142(3):516-22. PubMed ID: 2389902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
    Itoh K; Tilden AB; Kumagai K; Balch CM
    J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired in vitro interferon, blastogenic, and natural killer cell responses to viral stimulation in acquired immune deficiency syndrome.
    Hersh EM; Gutterman JU; Spector S; Friedman H; Greenberg SB; Reuben JM; LaPushin R; Matza M; Mansell PW
    Cancer Res; 1985 Jan; 45(1):406-10. PubMed ID: 2578099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
    J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of interferon-alpha 2 and interleukin-2 on natural killer cell activity in patients with acquired immune deficiency syndrome.
    Reddy MM; Chinoy P; Grieco MH
    J Biol Response Mod; 1984 Aug; 3(4):379-86. PubMed ID: 6332880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.